You are here
- Home
- Therapy Areas
- Oncology/Infection
A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine
- Disease
- cancer
- Drug Name
- vandetanib
- Generic Name
- Vandetanib=Caprelsa
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- I
- Start Date
- Feb 28, 2012
- Study Name
- D4200C00101
- Study Id
- D4200C00101
- ClinicalTrials.gov ID
- NCT01539655
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
